The N-terminal "beta -Barrel" Domain of 5-Lipoxygenase Is Essential for Nuclear Membrane Translocation*

Xin-Sheng Chen and Colin D. FunkDagger

From the Center for Experimental Therapeutics and Department of Pharmacology, University of Pennsylvania, Philadelphia, Pennsylvania 19104

Received for publication, September 7, 2000, and in revised form, October 9, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

5-Lipoxygenase is the key enzyme in the formation of leukotrienes, which are potent lipid mediators of asthma pathophysiology. This enzyme translocates to the nuclear envelope in a calcium-dependent manner for leukotriene biosynthesis. Eight green fluorescent protein (GFP)-lipoxygenase constructs, representing the major human and mouse enzymes within this family, were constructed and their cDNAs transfected into human embryonic kidney 293 cells. Of these eight lipoxygenases, only the 5-lipoxygenase was clearly nuclear localized and translocated to the nuclear envelope upon stimulation with the calcium ionophore A23187. The N-terminal "beta -barrel" domain of 5-lipoxygenase, but not the catalytic domain, was necessary and sufficient for nuclear envelope translocation. The GFP-N-terminal 5-lipoxygenase domain translocated faster than GFP-5-lipoxygenase. beta -Barrel/catalytic domain chimeras with 12- and 15-lipoxygenase indicated that only the N-terminal domain of 5-lipoxygenase could carry out this translocation function. Mutations of iron atom binding ligands (His550 or deletion of C-terminal isoleucine) that disrupt nuclear localization do not alter translocation capacity indicating distinct determinants of nuclear localization and translocation. Moreover, data show that GFP-5-lipoxygenase beta -barrel containing constructs can translocate to the nuclear membrane whether cytoplasmic or nuclear localized. Thus, the predicted beta -barrel domain of 5-lipoxygenase may function like the C2 domain within protein kinase C and cytosolic phospholipase A2 with unique determinants that direct its localization to the nuclear envelope.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Leukotrienes are potent lipid mediators of inflammation and anaphylaxis (1). They are generated by an initial reaction with the enzyme 5-lipoxygenase from arachidonic acid that has been liberated from membrane lipids (1-3). 5-Lipoxygenase is a 78-kDa protein found predominantly within inflammatory cell types (e.g. macrophages, mast cells, neutrophils, and eosinophils). The location of the enzyme is cell-type specific. In unstimulated neutrophils, it is found in the cytoplasm, whereas in alveolar macrophages and bone marrow-derived mast cells it is situated mainly in the nucleus (4-7). Transfection of 5-lipoxygenase cDNA leads to nuclear localized protein in HEK1 293, COS, NIH-3T3, and Chinese hamster ovary cells, as well as bone marrow-derived mast cells and RAW macrophages (8, 9).

Regardless of the cellular localization, 5-lipoxygenase undergoes a calcium-dependent translocation event to the nuclear membrane in activated inflammatory cells (5). Early studies documented a reversible, soluble to membrane compartment transition in neutrophils challenged with the calcium ionophore A23187 (10, 11). Experiments with RBL-2H3 cells demonstrated that the translocation to membranes required influx of extracellular calcium, which could be induced either with ionomycin or cross-linking of IgE receptors (12-14). The neutrophil 5-lipoxygenase cytosol to membrane translocation was associated with a loss of activity (11). However, in alveolar macrophages and RBL cells the translocation to membrane fractions activated 5-lipoxygenase activity (12, 15). It is generally regarded that the translocation event to the nuclear envelope is a necessary event in leukotriene formation. At this site there is an apparent transfer of substrate to 5-lipoxygenase by unknown mechanisms, via the integral membrane protein referred to as 5-lipoxygenase activating protein (16, 17).

5-Lipoxygenase was recently shown to directly bind two calcium ions (18). It has long been known that this enzyme is unique among lipoxygenases in its ability to have its activity stimulated by calcium (19, 20). Although this calcium stimulatory effect is not an absolute requirement for the purified enzyme, it is essential when the enzyme is present in intact cells, or in isolated preparations incubated with membranes or phospholipids (21, 22). 5-Lipoxygenase also possesses a nucleotide-binding site of unknown function and ATP is known to stimulate activity (23, 24).

There has been little, if any, insight to document the domain(s) within mammalian lipoxygenases that govern membrane translocation. The lipoxygenases are known to possess two domains based on the crystal structures of two soybean enzymes and the rabbit reticulocyte 15-lipoxygenase (25-28). The N terminus contains a beta -barrel region of ~110-115 (mammals) and 150 (plants) amino acids, in addition to the large non-heme iron containing catalytic domain at the C terminus. Sequence alignments between mammalian 15- and 5-lipoxygenases indicate ~33% identity in the predicted N-terminal domain and only around 10% homology between the corresponding region of plants and mammals. The function of the beta -barrel of lipoxygenases is unknown but it has been suggested that this domain, which bears resemblance to the C-terminal domain of certain lipases, is important for lipid binding (27). In fact, a recent study showed that this region within a cucumber lipoxygenase is important for binding to liposomes and lipid bodies (29).

Here, we show strong proof that the 5-lipoxygenase putative2 beta -barrel domain is unique among the mammalian lipoxygenase members in its ability to direct nuclear membrane translocation. Using green fluorescent protein-lipoxygenase fusions we present evidence for its necessity and sufficiency in nuclear translocation in real time using transfected cells.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Plasmid Constructs

5-Lipoxygenase Constructs-- The coding region for green fluorescent protein (GFP) from the vector pEGFP-C2 (CLONTECH) was ligated with the coding region for 5-lipoxygenase to make pEGFP-5LO as described previously (8). pEGFP-5LO was used for preparation of chimeric molecules and truncated 5-lipoxygenase cDNA constructs. GFP-tagged truncated 5LO constructs (see Fig. 2C), including pEGFP-5LO-(1-114), pEGFP-5LO-(115-673), pEGFP-5LO (N6-deletion), and pEGFP-5LO (N17-deletion) were prepared using polymerase chain reaction (PCR) and standard subcloning techniques (30). Chimeric lipoxygenases (see Fig. 4B) were engineered from pEGFP-5LO (8), pEGFP-12LO, and pEGFP-15LO (see below for preparation) and pEGFP-truncated 5LO templates. To prepare a GFP-tagged chimera, generally a restriction enzyme site was incorporated in a region of interest in the lipoxygenase DNA sequence by using the QuikChange Site-directed Mutagenesis kit (Stratagene) or PCR. Subsequently, ligation of restriction fragments was carried out using a Rapid DNA Ligation kit (Roche Molecular Chemicals). For example, to obtain pEGFP-N-15LO-(1-111)-C-5LO-(115-673), an EcoRI site was incorporated between the region encoding amino acid residue 111 and 112 of 15-LO through site-directed mutagenesis. EcoRI-cut fragment DNA encoding N-terminal 111 amino acids of 15-LO was cloned in EcoRI-digested pEGFP-5LO-(115-673). Ligation boundaries and PCR-generated DNA sequences in the above constructs were verified by automated DNA sequencing using the facilities of the Department of Genetics, University of Pennsylvania. More detailed information of these DNA constructs and mutagenic primers may be obtained upon request. The pEGFP-5LO-(1-80), pEGFP-5LO-(1-127), pEGFP-5LO-(1-166), pEGFP-5LO-(81-673), pEGFP-5LO-(C6-deletion), pEGFP-5LO-(H367Q), and pEGFP-5LO-(H550Q) were prepared previously (8).

pEGFP-12LO-- The XbaI insert from pcDNA1-6His12LX (31) was blunt end ligated into the blunted HindIII site of pEGFP-C2. The six-histidine tag was shown previously not to affect enzyme activity (31). The EGFP-tagged protein displayed high level 12-lipoxygenase activity in HEK 293-transfected cells (exclusive formation of 12-HPETE from arachidonic acid).

pEGFP-15LO-1-- An EcoRI/BglII fragment of the coding region for human 15-lipoxygenase (32) was cloned into the EcoRI and BamHI sites of pEGFP-C2. This construct yielded both 15-HETE and 12-HETE (9:1 ratio) from arachidonic acid in transfected cells similar to studies without the GFP tag (32).

pEGFP-15LO-2-- The coding region for human 15-lipoxygenase-2 was amplified by RT-PCR using primers and conditions based on the published sequence (33) starting with human hair RNA template (34). The PCR products were first cloned in pCR2.1 (Invitrogen) and sequences verified. Two fragments, a 0.9-kilobase EcoRI/AseI piece encoding the N-terminal region, and a 1.1-kilobase AseI/BamHI insert encoding the C terminus, were ligated in a three-fragment reaction with EcoRI/BamHI-digested pEGFP-C2. The construct when transfected into HEK 293 cells and subsequently incubated with arachidonic acid synthesized exclusively 15-HPETE.

pEGFP-12(R)LO-- The construction and characterization of this plasmid was described previously (34).

pEGFP-e12LO-- The original expression construct described previously (35) was cut with EcoRI, filled in with a Klenow reaction, and blunt end ligated into the SmaI site of pEGFP-C2.

pEGFP-8LO-- The coding region for murine 8-lipoxygenase was amplified by RT-PCR using primers and conditions based on the published sequence (36) starting with phorbol ester-treated epidermal RNA template from a 6-day-old mouse (35). The PCR products were first cloned in pCR2.1 (Invitrogen) and sequences verified. The EcoRI fragment with the correct sequence was first cloned into the expression vector pcDNA3 (Invitrogen) and then in pEGFP-C2. When transfected into HEK 293 cells 8-lipoxygenase activity was detected.

pEGP-eLO-3-- The sequence for this novel lipoxygenase was cloned exactly as done for 8-lipoxygenase described above based on the published sequence (37). No enzyme activity was detected with arachidonic acid substrate as described, presumably since this enzyme utilizes a different, as of yet undetermined, substrate.

Cell Culture and Transfection

HEK 293 cells were cultured in Dulbecco's modified Eagle's medium (Life Technologies, Inc.) supplemented with 10% fetal bovine serum. Cells growing in culture dishes, cover glass-bottomed culture dishes (for photography of living cells) or glass chamber slides were transfected with FuGENE 6 transfection reagent (Roche Molecular Biochemicals) according to the manufacturer's instructions. The transfected cells (15-20 h post-transfection) were used for translocation studies, fluorescence microscopy, and protein preparation for Western blot and lipoxygenase activity assays.

Translocation Studies and Fluorescence Microscopy

The HEK 293 cells on chamber slides, 15-20 h post-transfection, were washed twice with pre-warmed Dulbecco's modified Eagle's medium. For data documentation, the washed cells, 20-30 min post-incubation with 10 µM A23187 (Sigma) or 0.1% Me2SO (vehicle) in serum-free Dulbecco's modified Eagle's medium, were fixed with 2% paraformaldehyde in phosphate-buffered saline for 20 min. Slides were mounted with Gel/Mount and kept at 4 °C. Cell images were examined as described previously (8) for conventional fluorescence microscopy or using a Nikon E600 upright microscope equipped with Bio-Rad 1024 confocal imaging system. For time course analysis of translocation, the GFP fluorescence of living cells incubated in a 37 °C stage chamber, 15-20 h post-transfection, was recorded before and after addition of 10 µM A23187 using a Nikon TE300 inverted microscope equipped with Bio-Rad 1024 confocal system. Raw data photoimages were acquired by LazerSharp software (Bio-Rad) and processed further by Confocal Assistant and Adobe Photoshop programs.

Western Blot and Activity Assays

Cytosol proteins from transfected cells for Western blot and lipoxygenase activity assay were prepared as described previously (6). A mouse monoclonal antibody against GFP (Berkeley Antibody Co., 1:1000 dilution) was used for enhanced chemiluminescence detection. Activity assay of 12- and 15-lipoxygenases was carried out with 10,000 × g supernatant proteins of transfected cells in phosphate-buffered saline. The supernatants were incubated with 100 µM arachidonic acid for 15 min at 37 °C and the reactions were terminated with 2 volumes of stop solution (8). Activity assay for 5-lipoxygenase with addition of Ca2+ and ATP and reverse phase-high pressure liquid chromatography analysis of arachidonate metabolites (HETEs and HPETEs) by lipoxygenases were done as described previously (8) using an acetonitrile:H2O:acetic acid (65:35:0.1) mobile phase with additional assessment of leukotriene B4 production in transfected cells using UV detection at 270 or 280 nm. Authentic 5-H(P)ETE, LTB4, and 6-trans-12-epi-LTB4 standards (Cayman Chemical Co.) were chromatographed in parallel.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

5-Lipoxygenase Is Unique among Human and Murine Lipoxygenases in Its Ability to Translocate to the Nuclear Envelope-- Eight different GFP-lipoxygenase fusion constructs representing the major lipoxygenase forms unique to man and mouse were prepared and introduced into HEK 293 cells. The cells were visualized 15-20 h post-transfection either with or without calcium ionophore A23187 stimulation and were fixed for data documentation. In unstimulated cells, GFP-5LO was localized primarily within the nucleus as we had demonstrated previously (8). All other GFP-lipoxygenases were localized primarily to the cytosol of HEK 293 cells (left panels, Fig. 1, A and C). The lone exception, perhaps, was GFP-8LO, which distributed throughout the cell, in a pattern more reminiscent of GFP alone. All GFP-lipoxygenases were expressed as approx 110-kDa proteins by Western blot analysis using an anti-GFP antibody (Fig. 1B). Each lipoxygenase fusion yielded enzyme activity consistent with expression in a native nonfusion vector (e.g. pcDNA3). The three "classical" lipoxygenases (5-LO, 12-LO, and 15-LO-1) gave the highest enzyme activities, followed by 15-LO-2 and 8-LO and finally by the three epidermal lipoxygenases (12(R)-LO, eLO-1, and eLO-3), which gave very low to undetectable activity (Fig. 5 and data not shown).



View larger version (50K):
[in this window]
[in a new window]
 
Fig. 1.   Cellular localization and calcium ionophore A23187-induced translocation of 5-lipoxygenase is unique among mammalian lipoxygenases. HEK 293 cells were transfected with GFP-tagged mammalian lipoxygenase cDNA constructs. A, cellular location and translocation patterns of fluorescence carried by GFP-lipoxygenase fusion proteins were identified before (left panels) and after (right panels) application of calcium ionophore A23187 in living cells. Parafomaldehyde-fixed cells were used for image photographs (see "Experimental Procedures" for details). B, Western blot analysis. GFP-tagged lipoxygenase proteins were detected with a monoclonal anti-GFP antibody (1:1000 dilution). The sample number is equivalent to that in panel A. C, more detailed images of 5-lipoxygenase location before (left panels) and after (right panels) A23187-induced translocation with differential interference contrast (DIC) phase microscopy and fluorescence overlays. Note that separate fields of cells are depicted in the left and right panels for all images. Experiments were repeated at least three times with similar results.

When the cells were stimulated with A23187, there was a clear translocation to the nuclear envelope in nearly all GFP-5LO expressing cells as evidenced by a "ring-like" pattern (right panel, Fig. 1, A and C). There was little evidence, if any, for translocation to the nuclear membrane for the other seven GFP-lipoxygenase fusions (right panels, Fig. 1A).

The beta -Barrel Domain, but Not the Catalytic Domain, of 5-Lipoxygenase Is Essential for Nuclear Membrane Translocation-- Since lipoxygenases are known to possess two distinct domains (25-28), we prepared GFP-5LO fusions of the N-terminal beta -barrel and the C-terminal catalytic domains. The precise demarcation between the two domains is somewhat arbitrary because there is a "linking" region of about 15 amino acids between the last beta -strand of the beta -barrel and the first helical structure of the catalytic domain (residues 110-125) based on the rabbit reticulocyte 15-lipoxygenase structure (27). We chose a division between residues 114 and 115 of 5-lipoxygenase. In unstimulated cells, the GFP-5LO-(1-114) beta -barrel construct was localized primarily to the nucleus (Fig. 2A, top left panel) consistent with our previous finding of weak nuclear localizing signal (NLS) sequences within the first 80 residues of the protein (8). The GFP-5LO-(115-673) catalytic domain fusion protein was distributed throughout the cell (Fig. 2A, bottom left panel). Only GFP-5LO-(1-114) translocated to the nuclear membrane (Fig. 2A, top right panel) upon ionophore challenge indicating that the beta -barrel was essential for translocation. Extending the beta -barrel region (residues 1-127 or 1-166) yielded a similar translocation pattern but shortening the region from the C-terminal side (residues 1-80) abolished the ability to translocate (Fig. 2B). Truncation at the N terminus (N-6 deletion; 6 residues) did not affect translocation capacity but truncation of 17 amino acids did (Fig. 2B). Both truncations abolished enzyme activity consistent with data showing that lipoxygenases can tolerate N-terminal additions but not truncations (31, 38). The data for eight different constructs are summarized in Fig. 2C. The results suggest that determinants both near the N terminus (residues 6-17) and the C terminus (residues 80-114) of the beta -barrel are either directly involved or related to folding determinants that regulate interaction with the nuclear membrane.



View larger version (46K):
[in this window]
[in a new window]
 
Fig. 2.   The beta -barrel, but not the catalytic, domain of 5-lipoxygenase is essential for nuclear membrane targeting upon A23187 cell stimulation. A, HEK 293 cells were transfected with GFP-5LO-(1-114) beta -barrel or GFP-5LO-(115-673) catalytic domain constructs and fluorescence was visualized in unstimulated (left panels) and A23187 challenged (right panels) cells as described in the legend to Fig. 1 and under "Experimental Procedures." B, the GFP-5LO beta -barrel domain was shortened from the N terminus by six residues (N6-deletion), 17 residues (N-17 deletion), or C terminus (1-80) or extended to include additional residues linking the two domains () or including part of the catalytic domain (). Fluorescence was visualized as mentioned above. Note that separate fields of cells are depicted in the left and right panels for all images. Experiments were repeated three times with similar results. C, summary of results in tabular form depicting various constructs tested.

The time course of translocation for both the GFP full-length and beta -barrel 5-LO fusions was monitored in living cells (Fig. 3). Both nuclear localized fusions translocated, with earliest detectable events around 5 min after A23187 addition for the GFP-5LO beta -barrel construct. Complete "ring-like" patterns were discernable by 20-30 min for both. The translocation was faster with the GFP-beta -barrel construct than the full-length fusion.



View larger version (31K):
[in this window]
[in a new window]
 
Fig. 3.   Time course of A23187-induced translocation of GFP-5LO full-length (top panels) and ()-beta -barrel (bottom panels) fusion proteins in HEK 293 transfected cells. The cells were maintained at 37 °C and data collected on living cells using a Bio-Rad 1024 confocal imaging system.

Translocation Patterns and Enzymatic Activity of Chimeric beta -Barrel/Catalytic Domain GFP-lipoxygenases-- To assess further the importance of the 5-lipoxygenase beta -barrel with respect to translocation ability, eight distinct chimeric lipoxygenase constructs were made with 5-LO and either 15-LO-1 or 12-LO (the three so-called classical lipoxygenases)(Fig. 4). First, all chimeric constructs were cytoplasmic localized. The NLS sequences in 5-LO are complex and context dependent (i.e. there may be signals at both ends of the 5-LO molecule and not all fusions to different reporter proteins (e.g. GFP versus pyruvate kinase) are transported to the nucleus) (8, 9). Second, only chimeras with the complete beta -barrel of 5-LO translocated to the nuclear envelope. If the beta -barrel was truncated (1-80 residues), the chimeric protein no longer translocated. These particular chimeras, however, displayed enzymatic activity of the corresponding 12- or 15-lipoxygenase catalytic domains (Figs. 4B and 5). Third, chimeras with either the beta -barrel of 12-LO or 15-LO did not translocate to the nuclear envelope. Enzyme activity of these chimeras was dependent on the two-domain fusion boundary that, in general, had to be shifted toward the N terminus (Fig. 5). GFP-5LO and chimeras with the extended 5-LO catalytic domain were able to make 5-HPETE, 5-HETE, and products from LTA4 (LTB4 and 6-trans-LTB4 isomers) from arachidonic acid.



View larger version (44K):
[in this window]
[in a new window]
 
Fig. 4.   A23187-induced translocation of various GFP-lipoxygenase chimeras to the nuclear envelope requires the beta -barrel region of 5-lipoxygenase. A, the results from four different chimeras, N5LO-(1-127)-CP12LO-(126-663) (a 12-lipoxygenase enzymatically active chimera containing the N-terminal beta -barrel and interdomain connecting region of 5-lipoxygenase plus the C-terminal catalytic domain of platelet-type 12-lipoxygenase; top panels), NP12LO-(1-75)-C5LO-(81-673) (a 5-lipoxygenase enzymatically active chimera; second level panels), N5LO-(1-114)-C15LO-(112-663) (containing the beta -barrel of 5-lipoxygenase and catalytic domain of 15-lipoxygenase type 1; third level panels), and N15LO-(1-111)-C5LO-(115-673) (containing the beta -barrel of 15-lipoxygenase type 1 and catalytic domain of 5-lipoxygenase; bottom panels), respectively. B, summary of results in tabular form depicting these constructs and additional chimeras tested. The data are representative from experiments performed at least three times. 5-Lipoxygenase contains additional residues within the N-terminal region with respect to 12- and 15-lipoxygenases; thus, numbering may not always correspond in linear sequence.



View larger version (38K):
[in this window]
[in a new window]
 
Fig. 5.   Reverse phase-high pressure liquid chromatography chromatograms depicting formation of arachidonic acid metabolites in GFP-lipoxygenase-transfected HEK 293 cell supernatants. Panel I, relative amounts of HETE metabolites (UV absorbance at 235 nm) formed by: A, N5LO-(1-80)-C15LO-(76-663); B, N5LO-(1-80)-CP12LO-(76-663); D, NP12LO-(1-75)-C5LO-(81-673); and E, N5LO-(1-127)-CP12LO-(123-663). C, HETE standards. Results are presented in a qualitative fashion only at the same attenuation. No attempts were made to quantitate products. Panel II, comparison of products made by GFP-5LO (B) and the N15LO-(1-75) C5LO-(81-673) chimera (A) immediately after incubation. C, LTB4 and 5-H(P)ETE standards. The hydroperoxy compound, 5-HPETE, and its reduction product, 5-HETE (analysis at 235 nm) were detected in addition to LTB4 (formed by endogenous leukotriene A4 hydrolase present in incubations) and the two 6-trans-LTB4 isomers (nonenzymatic breakdown products of LTA4). The three latter products did not separate using the aqueous acetonitrile reverse phase-high pressure liquid chromatography system. IIB inset, using another system (methanol:H2O, 70:30 in 10 mM ammonium acetate, pH 7.8) better separation was achieved. Results are representative from at least three experiments.

Translocation Patterns of GFP-5LO Constructs with Iron-binding Ligand Mutations-- Mammalian lipoxygenases contain a non-heme iron atom bound by three histidine residues and an oxygen molecule on the C-terminal isoleucine (27). Point mutation of these critical histidines, or truncation of the C terminus, can severely cripple iron binding and abolishes enzyme activity (39). Most of these mutations also severely disrupt nuclear targeting indicative of specific folding requirements for nuclear localization (8). We tested the same mutants we made previously and found that the ability to translocate was unaffected by these inactivating mutations, in stark contrast to our results with nuclear targeting (Fig. 6).



View larger version (48K):
[in this window]
[in a new window]
 
Fig. 6.   Mutations to iron-binding ligands of 5-lipoxygenase do not affect ability to translocate to the nuclear envelope. A, mutations to disrupt iron ligands in 5-lipoxygenase H367Q (top panels), H550Q (middle panels), and deletion of the six C-terminal residues including the isoleucine oxygen ligand were prepared as described previously (8). A23187-induced translocation was assessed as in the legend to Fig. 1. Results are representative from at least three determinations. B, summary of results in tabular form depicting these constructs.



    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We have demonstrated using GFP-lipoxygenase fusion constructs transfected into HEK 293 cells and stimulated with calcium ionophore A23187 the following conclusions: 1) 5-lipoxygenase is unique in its nuclear localization and ability to translocate to the nuclear envelope when compared with other human and murine lipoxygenase family members; 2) the beta -barrel region of 5-lipoxygenase is necessary and sufficient for nuclear membrane translocation; 3) determinants at both ends of the beta -barrel region are important for translocation; 4) catalytically active functional chimeras of 5-lipoxygenase, 12-lipoxygenase, and 15-lipoxygenase type 1 can be created by correct association of the two domains at or close to the junction of the two domains; 5) 5-lipoxygenase nuclear targeting and translocation determinants are distinct; and 6) nuclear membrane translocation can occur from either the nuclear or cytoplasmic side.

Lipoxygenases possess a two-domain structure (25-28). The N-terminal beta -barrel domain of rabbit reticulocyte 15-lipoxygenase revealed striking homology with the C-terminal domain of various lipases. These domains on the distinct proteins share approximately the same size (115-125 amino acids) and both need to access lipid substrates at a membrane surface. A detailed characterization of the role of the beta -barrel in mammalian lipoxygenase function for substrate or membrane interaction has not been addressed previously. However, a recent report with a cucumber lipoxygenase indicated that the beta -barrel was necessary for transport from cytosol to lipid bodies (29). Among the mammalian lipoxygenase members identified so far, only the 5-lipoxygenase has a definite binding requirement for calcium ions (18). Calcium is essential for membrane association and has recently been shown to bind to the beta -barrel of 5-lipoxygenase (40).3 Thus, in many respects this domain appears to mimic the C2 domains of protein kinase C and cytosolic phospholipase A2, both which bind calcium and translocate to membranes (41, 42). What directs the 5-lipoxygenase, and not other lipoxygenases, specifically to the nuclear membrane is not clear. Besides the clear calcium binding and dependence on this cation in vivo, the 5-lipoxygenase appears unique among other lipoxygenases in having an accessory protein (5-lipoxygenase activating protein) that is important for substrate presentation. Moreover, certain interactions with other cytoskeletal and signaling molecules may represent another mode of directing 5-lipoxygenase translocation specifically to the nuclear envelope (43-45). The 5-lipoxygenase contains an "insertion" sequence of 5 residues in the beta -barrel that is not present in most mammalian 12- and 15-lipoxygenases (46). An aspartic acid residue within this stretch, as well as other determinants at both ends of the domain, could be important for calcium binding, and proper protein folding for optimum interactions with membrane sites analogous to cytosolic phospholipase A2 (47).

Although other lipoxygenases did not translocate to the nuclear envelope with A23187 stimulation in the transfected HEK 293 cells, this finding does not exclude translocation to other membrane sites for access of substrate. It is likely these other lipoxygenases interact in defined ways with membranes that is not evident in this system. Indeed, it has been shown that rat and human 12-lipoxygenases in platelets and tumor cells, as well as 15-lipoxygenase in reticulocytes and interleukin 4-treated monocytes translocate from cytosol fractions to undefined membrane sites (48-50).

In this study and a previous one (8), we were able to visualize 5-lipoxygenase cellular localization in living cells in real time or fixed with paraformaldehyde. The enzyme demonstrated an intrinsic capability to enter the nucleus of transfected cells indicative of specific NLS sequences. We showed that there were weak nontraditional NLS sequences somewhere within the first 80 residues of the protein (8) and Healy et al. (9) showed divergent results with weak determinants residing in a C-terminal basic region that were important for nuclear localization. The NLS determinants in the beta -barrel are definitely distinct from the translocation determinants. Mutations introduced to strong iron binding ligands (His-550 or terminal Ile-673 truncation) (39) changed the cellular localization from nuclear to cytoplasmic, whereas they had no effect on translocation. We interpret these results to mean that proper folding of the catalytic domain for appropriate contact with the beta -barrel and other potential chaperone proteins is essential for nuclear entry but is not important for translocation and association with the attendant membrane lipid and protein partners.

One other study has attempted to address the translocation of 5- and 15-lipoxygenases using truncation mutants and a chimeric approach with transfection into RAW264.7 macrophages (51). This study, unlike ours, was unable to assign a specific region within 5-lipoxygenase as important for membrane targeting. We are not exactly sure why divergent results were obtained but some points to consider are differences in cell type, transfection methods, cellular localization, and choice of construct design. We3 and Healy et al. (9) found that GFP-5LO localizes to the nucleus of this macrophage cell line instead of the cytosol as found in the study of Christmas et al. (51). However, here and in other studies in alveolar macrophages it has been shown that both cytoplasmic and nuclear pools of 5-lipoxygenase are capable of translocation to the nuclear envelope (5). We demonstrated with our chimeric approach that it was critical to carefully assign the junction between domains for obtaining active proteins. This finding indicates that important contacts between the two domains must be maintained for proper functional responses. Significant variability in enzyme activity and translocation capacity was evident with junction shifts either direction (±30-40 residues) from the initial chosen beta -barrel/catalytic domain junction (residue 115). Using this approach, translocation determinants could be definitely localized to the beta -barrel region in our studies. Previous studies in our laboratory showed that it was difficult to construct functional chimeras with 5-lipoxygenase and either 12- or 15-lipoxygenase in several locations within the center of the molecule within the catalytic domain (38). However, we and several other groups have been able to successfully alter oxygen insertional activity and product profiles with limited point mutations or small substitutions (38, 52-54).

Although we did not investigate in detail parameters affecting the time course of translocation, this process appeared to be slower than expected if functionally correlated to 5-HPETE or leukotriene biosynthesis in stimulated inflammatory cells. The GFP-5LO beta -barrel showed evidence of translocation by at least 5 min at 37 °C after ionophore stimulation and continued to proceed over the next 10-20 min. It is possible that the earliest events after ionophore stimulation may not be detectable by fluorescence assay of GFP due to sensitivity problems. Alternatively, the GFP-tag may actually slow the translocation process relative to nonfusion protein. Another aspect to consider is that HEK 293 cells do not normally express 5-lipoxygenase or 5-lipoxygenase activating protein and cellular machinery may not function analogously as in activated inflammatory cells. For instance, 5-lipoxygenase phosphorylation, which can occur in vitro (55), may not occur to the same extent or rapidity in these cells as in neutrophils.

In summary, we have shown that the beta -barrel domain of 5-lipoxygenase is necessary for nuclear envelope translocation. Addressing the concerted actions of calcium and ATP binding, in addition to phosphorylation status, with respect to translocation and functional correlation with leukotriene biosynthesis and enzyme inactivation at membrane sites will be important topics for future studies.


    ACKNOWLEDGEMENTS

We acknowledge the kind assistance of Dr. James Sanzo and Irina Chernysh at the Biomedical Imaging Core facility for assistance with confocal microscopy and John Lawson and Ting-Ting Kong for analysis of arachidonate metabolites.


    FOOTNOTES

* This work was supported by National Institutes of Health Grant HL58464.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Dept. of Pharmacology, Center for Experimental Therapeutics, University of Pennsylvania, 421 Curie Blvd., Rm. 814, Philadelphia, PA 19104-6160. Tel.: 215-898-0254; Fax: 215-573-9004; E-mail: colin@spirit.gcrc.upenn.edu.

Published, JBC Papers in Press, October 19, 2000, DOI 10.1074/jbc.M008203200

2 Since the crystal structure of 5-lipoxygenase has not been determined, it can only be assumed that this enzyme has a two-domain structure similar to other lipoxygenases with elucidated structures. Instead of using "putative" throughout the manuscript it is assumed that there is a N-terminal beta -barrel-like domain and a C-terminal catalytic domain and the word putative will not be used for the remainder of the text for simplicity.

3 X-S. Chen and C. D. Funk, unpublished observations.


    ABBREVIATIONS

The abbreviations used are: HEK, human embryonic kidney; GFP, green fluorescent protein; LO, lipoxygenase; RBL, rat basophilic leukemia; PCR, polymerase chain reaction; RT, reverse transcription; HETE, hydroxyeicosatetraenoic acid; NLS, nuclear localizing signal.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES


1. Samuelsson, B. (1983) Science 220, 568-575[Medline] [Order article via Infotrieve]
2. Samuelsson, B., and Funk, C. D. (1989) J. Biol. Chem. 264, 19469-19472[Free Full Text]
3. Lewis, R. A., Austen, K. F., and Soberman, R. J. (1990) N. Engl. J. Med. 323, 645-655[Medline] [Order article via Infotrieve]
4. Brock, T. G., McNish, R. W., Bailie, M. B., and Peters-Golden, M. (1997) J. Biol. Chem. 272, 8276-8280[Abstract/Free Full Text]
5. Brock, T. G., McNish, R. W., and Peters-Golden, M. (1995) J. Biol. Chem. 270, 21652-21658[Abstract/Free Full Text]
6. Chen, X. S., Naumann, T. A., Kurre, U., Jenkins, N. A., Copeland, N. G., and Funk, C. D. (1995) J. Biol. Chem. 270, 17993-17999[Abstract/Free Full Text]
7. Woods, J. W., Coffey, M. J., Brock, T. G., Singer, I. I., and Peters-Golden, M. (1995) J. Clin. Invest. 95, 2035-2046[Medline] [Order article via Infotrieve]
8. Chen, X.-S., Zhang, Y., and Funk, C. D. (1998) J. Biol. Chem. 273, 31237-31244[Abstract/Free Full Text]
9. Healy, A., Peters-Golden, M., Yao, J., and Brock, T. (1999) J. Biol. Chem. 274, 29812-29818[Abstract/Free Full Text]
10. Rouzer, C. A., and Samuelsson, B. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 7393-7397[Abstract]
11. Rouzer, C. A., and Kargman, S. (1988) J. Biol. Chem. 263, 10980-10988[Abstract/Free Full Text]
12. Wong, A., Hwang, S. M., Cook, M. N., Hogaboom, G. K., and Crooke, S. T. (1988) Biochemistry 27, 6763-6769[Medline] [Order article via Infotrieve]
13. Wong, A., Cook, M. N., Foley, J. J., Sarau, H. M., Marshall, P., and Hwang, S. M. (1991) Biochemistry 30, 9346-9354[Medline] [Order article via Infotrieve]
14. Wong, A., Cook, M. N., Hwang, S. M., Sarau, H. M., Foley, J. J., and Crooke, S. T. (1992) Biochemistry 31, 4046-4053[Medline] [Order article via Infotrieve]
15. Coffey, M., Peters-Golden, M., Fantone, J. C., and Sporn, P. H. (1992) J. Biol. Chem. 267, 570-576[Abstract/Free Full Text]
16. Miller, D. K., Gillard, J. W., Vickers, P. J., Sadowski, S., Leveille, C., Mancini, J. A., Charleson, P., Dixon, R. A., Ford-Hutchinson, A. W., Fortin, R., Gauthier, J. Y., Rodkey, J., Rosen, R., Rouzer, C., Sigal, I. S., Strader, C. D., and Evans, J. F. (1990) Nature 343, 278-281[CrossRef][Medline] [Order article via Infotrieve]
17. Mancini, J. A., Abramovitz, M., Cox, M. E., Wong, E., Charleson, S., Perrier, H., Wang, Z., Prasit, P., and Vickers, P. J. (1993) FEBS Lett. 318, 277-281[CrossRef][Medline] [Order article via Infotrieve]
18. Hammarberg, T., and Radmark, O. (1999) Biochemistry 38, 4441-4447[CrossRef][Medline] [Order article via Infotrieve]
19. Rouzer, C. A., Shimizu, T., and Samuelsson, B. (1985) Proc. Natl. Acad. Sci. U. S. A. 82, 7505-7509[Abstract]
20. Hogaboom, G. K., Cook, M., Newton, J. F., Varrichio, A., Shorr, R. G., Sarau, H. M., and Crooke, S. T. (1986) Mol. Pharmacol. 30, 510-519[Abstract]
21. Skorey, K. I., and Gresser, M. J. (1998) Biochemistry 37, 8027-8034[CrossRef][Medline] [Order article via Infotrieve]
22. Reddy, K. V., Hammarberg, T., and Radmark, O. (1999) Biochemistry 39, 1840-1848[CrossRef]
23. Zhang, Y., Hammarberg, T., Radmark, O., Samuelsson, B., Ng, C., Funk, C. D., and Loscalzo, J. (2000) Biochem. J. 351, 697-707[CrossRef][Medline] [Order article via Infotrieve]
24. Ueda, N., Kaneko, S., Yoshimoto, T., and Yamamoto, S. (1986) J. Biol. Chem. 261, 7982-7988[Abstract/Free Full Text]
25. Boyington, J. C., Gaffney, B. J., and Amzel, L. M. (1993) Science 260, 1482-1486[Medline] [Order article via Infotrieve]
26. Minor, W., Steczko, J., Stec, B., Otwinowski, Z., Bolin, J. T., Walter, R., and Axelrod, B. (1996) Biochemistry 35, 10687-10701[CrossRef][Medline] [Order article via Infotrieve]
27. Gillmor, S. A., Villasenor, A., Fletterick, R., Sigal, E., and Browner, M. F. (1997) Nat. Struct. Biol. 4, 1003-1009[Medline] [Order article via Infotrieve]
28. Skrzypczak-Jankun, E., Amzel, L. M., Kroa, B. A., and Funk, M. O., Jr. (1997) Proteins 29, 15-31[CrossRef][Medline] [Order article via Infotrieve]
29. May, C., Hohne, M., Gnau, P., Schwennesen, K., and Kindl, H. (2000) Eur. J. Biochem. 267, 1100-1109[Abstract/Free Full Text]
30. Davis, L. G., Dibner, M. D., and Battey, J. F. (1986) Basic Methods in Molecular Biology , Elsevier, New York
31. Chen, X. S., Brash, A. R., and Funk, C. D. (1993) Eur. J. Biochem. 214, 845-852[Abstract]
32. Funk, C. D., Furci, L., and FitzGerald, G. A. (1991) Adv. Prostaglandin Thromboxane Leukotriene Res. 21A, 33-36
33. Brash, A. R., Boeglin, W. E., and Chang, M. S. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 6148-6152[Abstract/Free Full Text]
34. Sun, D., McDonnell, M., Chen, X. S., Lakkis, M. M., Li, H., Isaacs, S. N., Elsea, S. H., Patel, P. I., and Funk, C. D. (1998) J. Biol. Chem. 273, 33540-33547[Abstract/Free Full Text]
35. Funk, C. D., Keeney, D. S., Oliw, E. H., Boeglin, W. E., and Brash, A. R. (1996) J. Biol. Chem. 271, 23338-23344[Abstract/Free Full Text]
36. Jisaka, M., Kim, R. B., Boeglin, W. E., Nanney, L. B., and Brash, A. R. (1997) J. Biol. Chem. 272, 24410-24416[Abstract/Free Full Text]
37. Kinzig, A., Heidt, M., Furstenberger, G., Marks, F., and Krieg, P. (1999) Genomics 58, 158-164[CrossRef][Medline] [Order article via Infotrieve]
38. Chen, X. S., and Funk, C. D. (1993) FASEB J. 7, 694-701[Abstract/Free Full Text]
39. Hammarberg, T., Zhang, Y. Y., Lind, B., Radmark, O., and Samuelsson, B. (1995) Eur. J. Biochem. 230, 401-407[Abstract]
40. Hammarberg, T., Provost, P., Persson, B., and Radmark, O. (2000) J. Biol. Chem. 275, 38787-38793[Abstract/Free Full Text]
41. Clark, J. D., Lin, L. L., Kriz, R. W., Ramesha, C. S., Sultzman, L. A., Lin, A. Y., Milona, N., and Knopf, J. L. (1991) Cell 65, 1043-1051[Medline] [Order article via Infotrieve]
42. Perisic, O., Paterson, H. F., Mosedale, G., Lara-Gonzalez, S., and Williams, R. L. (1999) J. Biol. Chem. 274, 14979-14987[Abstract/Free Full Text]
43. Lepley, R. A., and Fitzpatrick, F. A. (1994) J. Biol. Chem. 269, 24163-24168[Abstract/Free Full Text]
44. Lepley, R. A., Muskardin, D. T., and Fitzpatrick, F. A. (1996) J. Biol. Chem. 271, 6179-6184[Abstract/Free Full Text]
45. Provost, P., Samuelsson, B., and Radmark, O. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 1881-1885[Abstract/Free Full Text]
46. Funk, C. D. (1996) Biochim. Biophys. Acta 1304, 65-84[Medline] [Order article via Infotrieve]
47. Bittova, L., Sumandea, M., and Cho, W. (1999) J. Biol. Chem. 274, 9665-9672[Abstract/Free Full Text]
48. Baba, A., Sakuma, S., Okamoto, H., Inoue, T., and Iwata, H. (1989) J. Biol. Chem. 264, 15790-15795[Abstract/Free Full Text]
49. Hagmann, W., Gao, X., Zacharek, A., Wojciechowski, L. A., and Honn, K. V. (1995) Prostaglandins 49, 49-62[CrossRef][Medline] [Order article via Infotrieve]
50. Brinckmann, R., Schnurr, K., Heydeck, D., Rosenbach, T., Kolde, G., and Kuhn, H. (1998) Blood 91, 64-74[Abstract/Free Full Text]
51. Christmas, P., Fox, J., Ursino, S., and Soberman, R. (1999) J. Biol. Chem. 274, 25594-25598[Abstract/Free Full Text]
52. Sloane, D. L., Leung, R., Craik, C. S., and Sigal, E. (1991) Nature 354, 149-152[CrossRef][Medline] [Order article via Infotrieve]
53. Borngraber, S., Kuban, R. J., Anton, M., and Kuhn, H. (1996) J. Mol. Biol. 264, 1145-1153[CrossRef][Medline] [Order article via Infotrieve]
54. Jisaka, M., Kim, R. B., Boeglin, W. E., and Brash, A. R. (2000) J. Biol. Chem. 275, 1287-1293[Abstract/Free Full Text]
55. Werz, O., Klemm, J., Samuelsson, B., and Radmark, O. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 5261-5266[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.